scholarly journals Amniotic membrane-derived stem cells help repair osteochondral defect in a weight-bearing area in rabbits

2017 ◽  
Vol 14 (1) ◽  
pp. 187-192 ◽  
Author(s):  
Zhijin Zhang ◽  
Linru Zeng ◽  
Jun Yang ◽  
Lin Guo ◽  
Qiao Hou ◽  
...  
Keyword(s):  
Stem Cells ◽  
Amniotic Membrane ◽  
Osteochondral Defect ◽  
Weight Bearing ◽  
Weight Bearing Area

scholarly journals Human Amniotic Membrane as a Matrix for Endothelial Differentiation of VEGF-Treated Dental Stem Cells

2019 ◽  
Vol 12 (6) ◽  
pp. 599-613 ◽  
Author(s):  
Siti Nurnasihah Md Hashim ◽  
Muhammad Fuad Hilmi Yusof ◽  
Wafa’ Zahari ◽  
Hamshawagini Chandra ◽  
Khairul Bariah Ahmad Amin Noordin ◽  
...  
Keyword(s):  
Stem Cells ◽  
Amniotic Membrane ◽  
Endothelial Differentiation ◽  
Human Amniotic Membrane ◽  
Dental Stem Cells

Foot reconstruction in weight bearing area

1993 ◽  
Vol 16 (4-5) ◽  
Author(s):  
P. Roggero ◽  
Y. Blanc ◽  
S. Krupp
Keyword(s):  
Weight Bearing ◽  
Foot Reconstruction ◽  
Weight Bearing Area

Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells

Neurosurgery ◽  
2015 ◽  
Vol 79 (3) ◽  
pp. 481-491 ◽  
Author(s):  
Alexander E. Ropper ◽  
Xiang Zeng ◽  
Hariprakash Haragopal ◽  
Jamie E. Anderson ◽  
Zaid Aljuboori ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Growth Rate ◽  
Neural Stem Cells ◽  
Tumor Growth ◽  
Rat Model ◽  
Weight Bearing ◽  
Tumor Growth Rate ◽  
Intramedullary Spinal Cord ◽  
Human Neural Stem Cells

Abstract BACKGROUND There are currently no satisfactory treatments or experimental models showing autonomic dysfunction for intramedullary spinal cord gliomas (ISCG). OBJECTIVE To develop a rat model of ISCG and investigate whether genetically engineered human neural stem cells (F3.hNSCs) could be developed into effective therapies for ISCG. METHODS Immunodeficient/Rowett Nude rats received C6 implantation of G55 human glioblastoma cells (10K/each). F3.hNSCs engineered to express either cytosine deaminase gene only (i.e., F3.CD) or dual genes of CD and thymidine kinase (i.e., F3.CD-TK) converted benign 5-fluorocytosine and ganciclovir into oncolytic 5-fluorouracil and ganciclovir-triphosphate, respectively. ISCG rats received injection of F3.CD-TK, F3.CD, or F3.CD-TK debris near the tumor epicenter 7 days after G55 seeding, followed with 5-FC (500 mg/kg/5 mL) and ganciclovir administrations (25 mg/kg/1 mL/day × 5/each repeat, intraperitoneal injection). Per humane standards for animals, loss of weight-bearing stepping in the hindlimb was used to determine post-tumor survival. Also evaluated were autonomic functions and tumor growth rate in vivo. RESULTS ISCG rats with F3.CD-TK treatment survived significantly longer (37.5 ± 4.78 days) than those receiving F3.CD (21.5 ± 1.75 days) or F3.CD-TK debris (19.3 ± 0.85 days; n = 4/group; P <.05, median rank test), with significantly improved autonomic function and reduced tumor growth rate. F3.DC-TK cells migrated diffusively into ISCG clusters to mediate oncolytic effect. CONCLUSION Dual gene-engineered human neural stem cell regimen markedly prolonged survival in a rat model that emulates somatomotor and autonomic dysfunctions of human cervical ISCG. F3.CD-TK may provide a novel approach to treating clinical ISCG.

Sign in / Sign up

Export Citation Format

Share Document